Viking Therapeutics VKTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's accrued expenses?
- Viking Therapeutics (VKTX) reported accrued expenses of $39.14M in Q1 2026.
- How has Viking Therapeutics's accrued expenses changed year-over-year?
- Viking Therapeutics's accrued expenses increased by 244.2% year-over-year, from $11.37M to $39.14M.
- What is the long-term trend for Viking Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Viking Therapeutics's accrued expenses has grown at a 24.4% compound annual growth rate (CAGR), from $7.81M to $23.28M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.